Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma
Clinical and Molecular Hepatology · 2025
DOI: 10.3350/cmh.2024.0899 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2025. Verfasst von Da-Won Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, DNA Methylation, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Research Foundation of Korea, Ministry of Science and ICT.
Abstract (Originalsprache)
Background/Aims: Hepatocellular carcinoma (HCC) exhibits high de novo recurrence rates post-resection. Current post-surgery recurrence prediction methods are limited, emphasizing the need for reliable biomarkers to assess recurrence risk. We aimed to develop methylation-based markers for classifying HCC patients and predicting their risk of de novo recurrence post-surgery.
Methods
In this retrospective cohort study, we analyzed data from HCC patients who underwent surgical resection in Korea, excluding those with recurrence within one year post-surgery. Using the Infinium Methylation EPIC array on 140 samples in the discovery cohort, we classified patients into low- and high-risk groups based on methylation profiles. Distinctive markers were identified through random forest analysis. These markers were validated in the cancer genome atlas (n=217), Validation cohort 1 (n=63) and experimental Validation using a methylation-sensitive high-resolution melting (MS-HRM) assay in Validation cohort 1 and Validation cohort 2 (n=63).
Results
The low-risk recurrence group (methylation group 1; MG1) showed a methylation average of 0.73 (95% confidence interval [CI] 0.69–0.77) with a 23.5% recurrence rate, while the high-risk group (MG2) had an average of 0.17 (95% CI 0.14–0.20) with a 44.1% recurrence rate (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Program of Integrated OMICS for Biomedical Science, Yonsei University, Seoul, Korea.
- R&D center, LepiDyne Inc, Seoul, Korea.
- Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
- Department of Surgery, Seoul National University Hospital, Seoul, Korea.
- Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.
Förderung
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Kim, D. W., Park, J. H., Hong, S. K., Jung, M. H., Pyeon, J. O., Lee, J. Y., Suh, K. S., Yi, N. J., Choi, Y., Lee, K. W., & Kim, Y. J. (2025). Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2024.0899
Vancouver
Kim DW, Park JH, Hong SK, Jung MH, Pyeon JO, Lee JY, et al. Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma. Clinical and Molecular Hepatology. 2025. doi:10.3350/cmh.2024.0899
BibTeX
@article{Kim2025,
author = {Kim, Da-Won and Park, Jin Hyun and Hong, Suk Kyun and Jung, Min-Hyeok and Pyeon, Ji-One and Lee, Jin-Young and Suh, Kyung-Suk and Yi, Nam-Joon and Choi, YoungRok and Lee, Kwang-Woong and Kim, Young-Joon},
title = {Exploring methylation signatures for high de novo recurrence risk in hepatocellular carcinoma},
journal = {Clinical and Molecular Hepatology},
year = {2025},
doi = {10.3350/cmh.2024.0899}
}
EUVIMED